While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

including an extensive pipeline of therapeutics in clinical trials that could be the booster shot the stock needs to generate a rebound. It's been more than four years since Moderna rose to ...

including an extensive pipeline of therapeutics in clinical trials that could be the booster shot the stock needs to generate a rebound. Let's discuss the pros and cons of buying Moderna stock.

Despite this funding boost, Moderna has indicated that it does not expect this to contribute to its revenue in the near term, as the associated expenses are anticipated to offset the financial inflow.

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural for investors to wonder about where the biotech will go in the near ...

Moderna's chief executive. He stressed however that the mRNA-1273.214 candidate – which combines the current SpikeVax booster with an Omicron-specific candidate – is the company's lead ...

Moderna gains HHS backing for developing mRNA-based pandemic influenza vaccines, advancing clinical studies for up to five subtypes. Get Pro-Level Earnings Insights Before the Market Moves Tuesday ...

Jan 17 (Reuters) - The U.S. government has awarded Moderna (MRNA.O), opens new tab $590 million to advance the development of its bird flu vaccine, as the country doubles down on efforts to tackle ...

Moderna ends 2024 with the stock down to $40 and the market cap at only $15 billion. The biopharma traded over $400 back following COVID and even traded above $170 in the last year. The company ...

Highlighting Moderna's potential to find significant new streams of revenue in the near term. Taking it together, I rate Moderna as a speculative "Buy" for long-term investors with a high risk ...

In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against other firms end 2024 stronger with impressive gains. A lackluster trading persisted throughout the ...